ライフサイエンスコーパス: molecular disease

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 red for response by QPCR studies for minimal molecular disease.

2 tinib daily have variable levels of residual molecular disease.

3 ant disorder but rather a family of distinct molecular diseases.

4 Pauling & Castle established the notion of a molecular disease (3).

5 rk, which recognized sickle-cell anemia as a molecular disease, and with Ingram's demonstration of a

6 Pauling's concept of "molecular disease," based on this discovery, opened a ne

7 Thus, there is a high clinical need for molecular disease biomarkers to aid in differentiating t

8 Detection of molecular disease by immunoglobulin high-throughput sequ

9 Detectable molecular disease by PCR was highly predictive of diseas

10 overlap or distinguish the diseases in each molecular disease category.

11 overview of techniques used for noninvasive molecular disease detection in selected myeloid and lymp

12 Although the WARBM molecular disease etiology remains unclear, both the bs

13 ib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite sign

14 tion for Bcl-2 gene rearrangements to detect molecular disease, however, may identify patients with e

15 Detection of molecular disease in the plasma often preceded PET/CT de

16 decades that followed, other cytogenetic and molecular disease markers have been described and effect

17 ed by diagnostic algorithms that incorporate molecular disease markers, which complement histological

18 Molecular disease measured from plasma, compared with ci

19 , and provide comprehensive insight into the molecular disease mechanisms of cystic fibrosis caused b

20 To understand the molecular disease mechanisms of this disease, we investi

21 ht the role of ctDNA as a minimally invasive molecular disease monitoring strategy in MDS.

22 ntal involvement may then implicate cellular/molecular disease pathways for treatment and targeted ph

23 vances in AMD research also highlight common molecular disease pathways with other neurodegenerative

24 state cancer incidence, and understanding of molecular disease progression is advancing rapidly.

25 ve for FDG, reserving PET to be used for the molecular disease-specific amyloid and tau tracers.

26 nt and difficult problem is the discovery of molecular disease subtypes characterized by relevant cli

27 g, sickle-cell disease) were among the first molecular diseases to be identified, and have been inves

28 Before treatment, molecular disease was detected in the plasma of 82% of p

29 However, molecular disease was detected significantly more freque

30 a-GAL brings Fabry disease into the realm of molecular diseases, where insights into the structural b

31 o an understanding of the complexity of this molecular disease with protean manifestations.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。